Cimavax-EGF, a Cuban therapeutic vaccine against lung cancer, conquers the scientific community and the population of the United States based on the achievements compiled in studies carried out.
For the first time in Cuba, the patient will undergo a molecular and a clinical diagnosis for this disease.
Cuban President Miguel Díaz-Canel praised today the success of the COVID-19 pediatric immunization program launched in the country in preventing any decease among children and shared the results of a study by the Pedro Kourí Tropical Medicine Institute proving that, during the Omicron surge, the vaccine Soberana was 90.1% effective in the 2 to 5 age group and 95.8% in children between the ages of two and eighteen.
The president of Cuba, Miguel Diaz-Canel, alerted the authorities of the Ministry of Public Health (MINSAP) about the need to take measures to reinforce the population's perception of risk in the face of Covid-19.
The inclusion of patients in the NeuroEpo clinical trial (CT) in mild and moderate Alzheimer's will begin in Holguín next September, after a period of organization and evaluation in the territory, where the study will be assumed by the Provincial Group of CT and will include a multidisciplinary team of neurologists, psychiatrists, neuropsychologists, among other specialties.